Zevra Therapeutics, Inc. ZVRA OLPRUVA — Revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s olpruva — revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net?
- Zevra Therapeutics, Inc. (ZVRA) reported OLPRUVA — revenue, net of $300K in Q1 2026.
- How has Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net changed year-over-year?
- Zevra Therapeutics, Inc.'s OLPRUVA — revenue, net increased by 200.0% year-over-year, from $100K to $300K.
- What does OLPRUVA — revenue, net mean?
- This metric represents the total net sales generated from the commercialization of the OLPRUVA product line after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption and commercial traction within the rare disease therapeutic space. Tracking this revenue stream helps investors evaluate the company's ability to successfully execute its commercial strategy for specialized orphan drug assets.